Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its proprietary SHR-4685 has...
AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:...
OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
OTR Therapeutics announced a strategic collaboration with LG Chem (KRX: 051910) to jointly accelerate the...
Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
Hangzhou Qihan Biotech Engineering Life (“Qihan Biotech”) announced that its QT-019C cell injection has received...
Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)...
Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights
Transcenta Holding Limited (HKG: 6628) announced it will return select collaborative products to Eli Lilly...
Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the formal establishment of a Joint Laboratory...
Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million
Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian...
LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors
LTZ Therapeutics announced that its second drug candidate, LTZ-232, has received Investigational New Drug (IND)...
Peking University Third Hospital Introduces World’s First PTH Replacement Therapy Palopegteriparatide Through Beijing Rare Disease Pilot Zone
Peking University Third Hospital has officially introduced palopegteriparatide, the world’s first and only approved parathyroid...
MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001
MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series...
Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure
Shanghai Stexo Biotechnology Co., Ltd. announced that its proprietary extracellular vesicle drug STX11101 injection, derived...
Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) and Whitehawk Therapeutics, Inc. (NASDAQ: WHWK)...
Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China
Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:...
China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List
China’s National Medical Products Administration (NMPA), in coordination with the Ministry of Public Security and...
China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) unveiled the “PIONEER” (Propel...
Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
Immunocon and MabGalaxy announced a comprehensive upgrade of their strategic cooperation, integrating artificial intelligence and...
Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition...
Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American...
CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the...